The portfolio has also shifted decisively toward biologics and advanced therapies — antibodies, RNAi agents, cell and gene therapies, radioligands and vaccines — using a regime originally built with small molecules in mind. And extension is not a formality: roughly one in eighteen applications was refused or withdrawn, and filings hit a record in 2025 before continuing into 2026. The window to apply is narrow and the eligibility rules unforgiving; the rights go to those who treat timing as a discipline, not an afterthought.

The extended-expiry dates cluster heavily between 2030 and 2034 and stretch out to 2041 — this is, in effect, a published timetable of when each competitor’s protection lapses and when generic or biosimilar entry opens. That is competitive intelligence for challengers and an early-warning system for incumbents. Look closer and you see the architecture: scores of molecules are defended not by one patent but by three or more separately extended patents layered around formulation, salt forms and methods of use. None of this happens by accident.

Lifecycle protection is engineered years ahead — through disciplined filing strategy, deadline rigour and a deliberate stack of rights — the public record will reveal whether you did it well.

Read the calendar and learn from it before your competitors do.

Here’s the data: https://docs.google.com/spreadsheets/d/1wJ7OIdmSfBxNIjJnRDCBNwp2FEiJY74k/edit?gid=920856139#gid=920856139

Here’s Rodney Cruise’s post in LinkedIn: https://www.linkedin.com/feed/update/urn:li:activity:7464445225080557568/

When individuals can run projects end‑to‑end, the organisation’s IP footprint becomes more fluid — and more dependent on whether leaders have built the systems to capture, protect, and leverage the innovation emerging from these autonomous workflows.

Faster cycles mean more tacit knowledge being created in the flow of work, and more risk that it evaporates or walks out the door if not deliberately captured. The HI‑C model rewards those who can connect craft to commercial outcomes, which is exactly where disciplined IP strategy earns its keep: identifying what is strategically differentiating, locking in ownership early, and ensuring that rapid experimentation doesn’t outpace governance.

The opportunity is clear — a leaner, more empowered organisation can generate more protectable assets, more quickly. The risk is equally clear — without structure, you end up with fragmented know‑how and no defensible position. The takeaway: if you’re flattening your org and accelerating execution, your IP strategy must flatten and accelerate with it.

Read the original article here.

The Court allowed the obviousness and PTE‑related amendments because they were grounded, timely once recognised, and strategically coherent. But it refused the late‑breaking best‑method case because it was diffuse, exploratory, and would have derailed a tightly scheduled path to trial. Courts reward structured, well‑reasoned strategy and penalise fishing expeditions dressed up in pleadings.

There’s a broader pattern worth noting. As product lifecycles shorten and regulatory‑linked patent extensions become more valuable, the strategic premium on precision increases. This judgment reinforces that your litigation posture is part of your IP strategy — not an afterthought. A party that cannot articulate its theory of invalidity early and with discipline risks losing the opportunity to run it at all.

Conversely, a party that anticipates pressure points early, aligns its technical and legal teams, and builds a coherent narrative is better positioned to protect or challenge market exclusivity.

Treat amendment decisions as strategic investments. The organisations that win are those that structure their IP strategy to move quickly, argue clearly, and keep the commercial timeline front of mind.

The strategic thread running through all three failures was the same: the patentee had broadened its divisional claims by removing specific limitations (a named switch type and a two-sensor arrangement), but the wider claims weren’t disclosed in the original PCT filing, so they slipped to a later priority date — and the Court confirmed that best method is assessed at the filing date of the divisional, not the parent, meaning improvements learned in the years between had to be disclosed and weren’t.

A claim is only as strong as the disclosure and the priority date underneath it, and “broader” and “stronger” are not the same thing. Three checks are worth running across any portfolio built on divisionals: first, does each broadened claim still trace to disclosure in the earliest application, or has it drifted to a priority date that exposes it to intervening prior art; second, where you widened a claim by stripping a limitation, did you disclose the best method known at the divisional filing date for that broader invention; third, are you filing divisionals to protect genuinely distinct inventions, or simply to keep options open in a way that manufactures risk.

Patentees should review portfolios for vulnerability to this ground and consider filing further divisionals to cure any later-discovered best method; international applicants are most exposed, since few jurisdictions outside Australia carry a standalone best-method requirement. Disciplined claim strategy, in the end, is knowing what not to claim — and knowing what you must disclose the moment you decide to claim it.

Read the case here: The NOCO Company v Brown and Watson International Pty Ltd [2026] FCAFC 44

MicKinsey’s suggested remedy translates almost directly to IP. First, build genuine understanding of the landscape before reviewing any plan—treat the portfolio as a value driver, not a compliance line item. Second, force real debate before a strategy is set: ask what a competitor or an acquirer would do with your IP, and whether your protection actually maps to where you create value. Third, wrestle the options to the ground—build, license, acquire or divest—and tie each to capital and talent allocation rather than leaving it to legal housekeeping. Done well, this is what turns IP from a cost centre into a lever for bolder, better-resourced moves.

The discipline isn’t about getting the filings right. It’s about how thoughtful owners decide where to compete.

Worth a read: McKinsey, Tapping the strategic potential of boards.

Amarin held a method-of-use patent on the cardiovascular indication for its drug Vascepa. Hikma launched a generic under a skinny label that carved out that patented use and kept only the off-patent one. Amarin’s induced infringement claim leaned on the totality of Hikma’s conduct: its label, its leaflet, its website, its investor press releases. The Court was unmoved. Inducement requires affirmative steps to encourage infringement, it held — not statements a physician could read as encouragement, and certainly not routine regulatory compliance, standard equivalence language, or what the drug didn’t say. Omissions, vagueness and “obvious alternative explanations” don’t cross the line.

For brand- side IP Managers, a second medical use patent is a real asset, if you can, figure out and claim all commercially viable indications – because the generic and biosimilar companies will. For generics and biosimilar teams, it confirms that a disciplined carve-out plus genuinely neutral commercial conduct is a defensible launch strategy, though note that Australian courts (Apotex v Sanofi, the pregabalin litigation) look hard at real-world market behaviour and won’t always reach the same result.

The takeaway for any IP-intensive organisation: your competitive position is decided long before litigation, in the choices about what you patent and how you behave commercially around it. Treat IP strategy as a business decision, not a filing exercise — and design your evidence trail, on both sides of the fence, before you need it.

How you transfer value matters as much as whether you transfer it. Courts and juries will read the commercial logic of a settlement, not just its wording — and an arrangement engineered to suppress competition will be treated as exactly that, however carefully it is drafted.

Tie any agreed entry date to a genuine, documented assessment of patent strength. Scrutinise royalty schedules, authorised-generic rights and every other lever for incentives that look exclusionary in hindsight. And note the timeline: a 2014 deal was still being unwound in 2026 — settlement decisions have a very long risk period. Strong IP strategy isn’t only about owning strong patents. It’s about structuring the deals around them so the economics tell the same story as the paperwork.

Katten’s analysis of the verdict: https://katten.com/lessons-from-landmark-jury-verdict-in-amitiza-reverse-payment-antitrust-case — and the reporting from FiercePharma: https://www.fiercepharma.com/pharma/takeda-slapped-885m-verdict-pay-delay-antitrust-case

For potential defendants, it means a German (or other UPC-state) corporate footprint can pull your UK and other foreign exposure into one court—worth factoring into where you incorporate, manufacture, and hold title.

But accepting jurisdiction is one thing; exercising it is another, and that distinction is where the commercial discipline lies. The Court built in safeguards through comity: it can grant relief on foreign designations subject to a condition that the patent isn’t later found invalid by the competent national court, giving defendants a clear incentive to move fast in national revocation forums if they want to resist a long-arm injunction. And clearing the jurisdictional hurdle guarantees nothing on the merits—Fujifilm’s UK claim ultimately failed because, under UK law, supplying goods abroad to a party that later imports them isn’t enough for joint tortfeasorship.

The takeaway for IP strategy: map your domicile and supply-chain structure against this expanded reach, decide early whether to maintain or withdraw extra-territorial claims, and remember that winning jurisdiction is the start of the contest, not the end of it.

Bristows’ full Rapid Reaction analysis is worth reading in full: https://inquisitiveminds.bristows.com/post/102n0w7/rapid-reaction-upc-court-of-appeal-clarifies-the-approach-to-long-arm-claims-fu

For IP-intensive businesses the lesson is uncomfortable but clear: inbound IP is a constraint, not a windfall. Every drawing, sample and spec that arrives under an obligation of confidence narrows what you can later claim as your own — and disregard of that line is what invited additional damages here.

The appeal is just as instructive for what it corrected. The Court set aside a constructive trust that had handed the manufacturer the entire design, because the distributor was a genuine co-designer — remedies track contribution, not punishment. More striking is the threats ruling: a letter demanding undertakings and reserving the right to sue is prima facie an unjustified threat unless you can prove infringement, and quietly dropping the claim later will not save you.

Three takeaways for leaders and in-house counsel:

1. fix ownership in writing before development starts;
2. treat others’ confidential material as off-limits, not raw material; and
3. never send an enforcement letter you are not prepared to back in court.

Disciplined IP strategy is less about owning the most rights than knowing precisely how to use them.

Bodum’s double-walled glasses enjoyed a decade of design protection; once it expired, Maxwell & Williams openly copied the exact shape, admitted as much, and sold a near-identical product more cheaply. Bodum tried to stretch its protection through misleading-conduct and passing-off claims, and lost. The strategic reason matters more than the result: Bodum had never built a secondary reputation in the shape itself. Consumers recognised the BODUM word mark and logo — not the bare silhouette. Ironically, the strength of the brand undercut the claim. Buyers identified the product by the name on it, so a glass without that name read as “not Bodum,” not “a cheaper Bodum.” Deliberate copying, the Court confirmed, is not the same as an intention to deceive — and a strong rival brand plus clear labelling will usually defeat the claim.

For IP-intensive businesses, the lesson is about sequencing and evidence, not litigation. Treat every finite right — a design, a patent — as a window to build something durable, not as the protection itself. If a shape is commercially important, work deliberately to make it distinctive of you: promote the shape as a brand signifier, consider a shape trade mark (renewable indefinitely), and keep the proof — distribution figures, readership, campaigns that feature the shape without the logo.

Bodum’s marketing was extensive but unfocused: the glasses were two of more than twenty-five double-walled designs, rarely shown unbranded, and the evidence of standalone shape recognition simply wasn’t there. The disciplined move is to convert a temporary monopoly into lasting brand equity before the clock runs out — and to document that recognition as you go, so the get-up can carry its own weight when the registration can’t.

Full decision here: https://www.austlii.edu.au/cgi-bin/viewdoc/au/cases/cth/FCA/2026/238.html